Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 2
2006 1
2007 2
2008 2
2010 2
2011 4
2012 3
2014 1
2015 1
2016 1
2017 4
2018 5
2019 4
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. Beltran H, et al. Among authors: kelly k. Clin Cancer Res. 2019 Dec 1;25(23):6916-6924. doi: 10.1158/1078-0432.CCR-19-1423. Epub 2019 Jul 30. Clin Cancer Res. 2019. PMID: 31363002 Free PMC article.
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.
Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, Li J, Qiu X, Hong AL, Botta G, Golumb L, Richter C, So J, Sandoval GJ, Giacomelli AO, Ly SH, Han C, Dai C, Pakula H, Sheahan A, Piccioni F, Gjoerup O, Loda M, Sowalsky AG, Ellis L, Long H, Root DE, Kelly K, Van Allen EM, Freedman ML, Choudhury AD, Hahn WC. Hwang JH, et al. Among authors: kelly k. Cell Rep. 2019 Nov 19;29(8):2355-2370.e6. doi: 10.1016/j.celrep.2019.10.068. Cell Rep. 2019. PMID: 31747605 Free PMC article.
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Karzai F, et al. Among authors: kelly k. J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2. J Immunother Cancer. 2018. PMID: 30514390 Free PMC article.
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, Alilin AN, Karzai FH, Dahut WL, Corey E, Kelly K. Beshiri ML, et al. Among authors: kelly k. Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. doi: 10.1158/1078-0432.CCR-18-0409. Epub 2018 May 10. Clin Cancer Res. 2018. PMID: 29748182 Free PMC article.
Profiling prostate biology.
Kelly K. Kelly K. Science. 2020 May 1;368(6490):467-468. doi: 10.1126/science.abb7052. Science. 2020. PMID: 32355016 No abstract available.
Reprogramming to resist.
Kelly K, Balk SP. Kelly K, et al. Science. 2017 Jan 6;355(6320):29-30. doi: 10.1126/science.aam5355. Science. 2017. PMID: 28059730 No abstract available.
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y. Marzi L, et al. Among authors: kelly k. Clin Cancer Res. 2019 Oct 15;25(20):6206-6216. doi: 10.1158/1078-0432.CCR-19-0419. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409613 Free PMC article.
34 results